Recently, SPX has emerged as a new target for drug design/therapeutic strategy, e.g., for type 2 diabetes mellitus (T2DM) treatment [3], gastrointestinal disease treatment [9], and prediction of insulin resistance in patients with nonalcoholic fatty liver disease [10]. Here, SPX is linked to metabolic dysfunction-associated steatotic liver disease.